Show simple item record

dc.contributor.authorRayman, Margaret P
dc.contributor.authorBlundell-Pound, Gabrielle
dc.contributor.authorPastor-Barriuso, Roberto 
dc.contributor.authorGuallar, Eliseo 
dc.contributor.authorSteinbrenner, Holger
dc.contributor.authorStranges, Saverio
dc.identifier.citationPLoS One. 2012;7(9):e45269es_ES
dc.description.abstractBACKGROUND: Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen. METHODS: In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available. RESULTS: Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96). CONCLUSIONS: These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.es_ES
dc.description.sponsorshipThe authors acknowledge the financial support of Cancer Research UK (formerly the Cancer Research Campaign) for the UK PRECISE Pilot Trial. Funding for ELISA kits for adiponectin measurement was provided by the University of Surrey and by Pharma Nord, Denmark. The work of HS was supported by a grant (STE 1782/2-2) from Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.subject.meshAdiponectin es_ES
dc.subject.meshAged es_ES
dc.subject.meshBiomarkers es_ES
dc.subject.meshDiabetes Mellitus, Type 2 es_ES
dc.subject.meshDietary Supplements es_ES
dc.subject.meshDouble-Blind Method es_ES
dc.subject.meshDrug Administration Schedule es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPilot Projects es_ES
dc.subject.meshPlacebos es_ES
dc.subject.meshRisk es_ES
dc.subject.meshSelenium es_ES
dc.subject.meshSelenoprotein P es_ES
dc.titleA randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectines_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderCancer Research UK (Reino Unido) 
dc.contributor.funderUniversity of Surrey (Reino Unido) 
dc.contributor.funderPharma Nord (Reino Unido) 
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional